Padlas (Vildagliptin)

Vildagliptin, the active ingredient in Padlas, is a dipeptidyl peptidase‑4 (D‑type inhibitor) presented as a 50 mg tablet for oral use. It helps improve blood glucose control in adults with type 2 diabetes mellitus. GNH India supplies Padlas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Padlas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Elpen Pharmaceutical Co. Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Padlas (vildagliptin) acts on the incretin pathway to improve glycaemic control in type 2 diabetes. It is used in the following recognised indications:

Type 2 Diabetes Mellitus: Improves fasting and post‑prandial blood glucose levels when used with diet, exercise and other antidiabetic agents.
Combination Therapy with Metformin: Provides additional HbA1c reduction when added to metformin in patients inadequately controlled on metformin alone.
Combination Therapy with a Sulfonylurea: Enhances overall glycaemic control when combined with a sulfonyl‑honey

How It Works

Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the rapid breakdown of the incretin hormones GLP‑1 and GIP. This prolongs their activity, leading to glucose‑dependent stimulation of insulin secretion and

Side Effects

Vildil…

Padlas (Vildagliptin)

Manufacturer / TM Owner

Indications & Clinical Uses

How It Works

Side Effects

Frequently Asked Questions